Needham Reiterates Buy on CRISPR Therapeutics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum reiterated a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and maintained a $90 price target.
April 11, 2024 | 10:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum reiterated a Buy rating on CRISPR Therapeutics and maintained a $90 price target.
Analyst ratings, especially from reputable firms like Needham, can significantly influence investor sentiment and stock prices. A reiterated Buy rating and a maintained price target suggest a strong vote of confidence in CRISPR Therapeutics' prospects, potentially leading to positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100